BMO Capital Sees Almost 300% Upside On Centessa Stock

BMO Capital has initiated coverage on Centessa Pharmaceuticals plc CNTA with a price target of $19 (293% upside), and an Outperform rating.
The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD. Early ZF874 data (N=2) demonstrated therapeutic efficacy in patients, but liver toxicity was also flagged.
Centessa is currently trying to identify an optimal dose that circumvents the liver toxicity while maintaining efficacy. The data readout is expected in 2H22.
The analyst notes that the hemophilia program with potential FDA approval in 2026 could drive short-term upside.
SerpinPC is differentiated against most approved/investigational hemophilia treatments as it doesn’t trigger thrombosis and comes with convenient dosing.
Read Next: Centessa Stock Surges On Positive Data From Hemophilia Candidate.
An open-label extension study readout is planned for 4Q22.
Price Action: CNTA shares are up 16.67% at $4.83 during the market session on the last check Friday.

Analyst Calendar